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Abstract   
 
Background:  Tobacco smoking or secondhand smoke exposure is the leading cause of 
preventable death in the U.S.  Between 2000 and 2004, an estimated 442 100 deaths were 
attributable to smoking in the United States.  Products exist that can increase cessation 
rates and reduce this risk.  E-cigarettes have gained popularity for smoking 
cessation/reduction and mitigation of withdrawal effects while still continuing to have a 
“smoking experience”.  Research investigating the efficacy and safety of electronic 
cigarettes is limited.  This systematic review is a summary of applicable studies regarding 
the efficacy and safety of electronic cigarettes as a tobacco cessation product. 
 
Methods:  An exhaustive medical literature search was performed using Medline-OVID, 
CINAHL, and Health Reference Center-Academic using the keywords: electronic 
cigarette, e-cigarette, and e cigarette.  The included articles were assessed for quality 
utilizing GRADE.  A search of the National Institute of Health (NIH) clinical trials 
website was performed to detect currently registered trials.     
 
Results:  Three studies meeting inclusion criteria were included in this systematic 
review.  All studies reported increased cessation rates without significant adverse effects.  
The first study, a randomized controlled trial with 657 participants, lacked statistical 
power to detect difference.  The second study, a randomized control design study with 
300 participants demonstrated statistical significance.  The third study, an observational 
study with 40 participants, reported results that could be due to chance. 
 
Conclusion:  E-cigarettes have been shown to increase cessation rates without significant 
adverse effects.  However, quality of the e-cigarette was inconsistent.  There is no 
regulatory oversight to guarantee safety in the U.S.  Evidence is insufficient to properly 
assess the benefits and harms of e-cigarettes.  There is a lack of evidence to support 
routinely recommending the use of electronic cigarettes for smoking cessation at this 
time.  Further randomized controlled studies are in progress.   
 
Keywords:  Electronic Cigarette, e cigarette, e-cigarette, tobacco, cessation, efficacy 
 
 
  
4 
 
Table of Contents 
 
Biography ............................................................................................................................ 2 
Abstract ............................................................................................................................... 3 
Table of Contents ................................................................................................................ 4 
List of Tables ...................................................................................................................... 5 
List of Abbreviations .......................................................................................................... 5 
BACKGROUND ................................................................................................................ 6 
METHODS ......................................................................................................................... 9 
RESULTS ........................................................................................................................... 9 
DISCUSSION ................................................................................................................... 21 
CONCLUSION ................................................................................................................. 24 
References ......................................................................................................................... 26 
Table I. Characteristics of Reviewed Studies ................................................................... 30 
 
 
  
5 
 
List of Tables  
 
Table I:      Characteristics of Reviewed Studies  
 
 
List of Abbreviations 
 
nAChRs ……………………………………………………nicotinic cholinergic receptors 
NRT........................................................................................nicotine replacement therapy 
ENDD………………………………………………….electronic nicotine delivery device 
CO………………………………………………………………………..carbon monoxide 
eCO…………………………………………………………...…exhaled carbon monoxide 
CI……………………………………………………………………...Confidence Interval 
ppm………………………………………………………………………..parts per million 
FDA…………………………………………….…….U.S. Food and Drug Administration 
WHO………………………………………………………..…World Health Organization 
E-Cigarettes……………………………………………………..……Electronic Cigarettes 
GNSBQ………………………...…… Glover Nilsson Smoking Behavioral Questionnaire  
NNT……………………………………………………………...Number Needed to Treat 
 
 
 
  
6 
 
The Efficacy and Safety of Electronic 
Cigarettes as a Tobacco Cessation 
Product 
BACKGROUND 
 
In the United States, tobacco smoking or secondhand smoke exposure is the 
leading cause of preventable death.  There is an estimated 8.6 million who are seriously 
ill as a result of this exposure.1  Between 2000 and 2004, an estimated 442 100 deaths 
were attributable to smoking in the United States.2   
Tobacco contains (s)-nicotine which binds to nicotinic cholinergic receptors 
(nAChRs).  When tobacco is smoked, (s)-nicotine is carried into the lungs and ultimately 
absorbed into the pulmonary venous circulatory system.  The nicotine travels from the 
pulmonary venous circulation to the arterial circulation and into the brain where it binds 
nAChRs.  These receptors are found in both the peripheral and central nervous systems.  
It is believed that the cardiovascular effected of nicotine are a result of the binding of one 
subunit of the nAChRs.3  Once the receptor is bound by (s)-nicotine, the 
neurotransmitters dopamine, norepinephrine, acetylcholine, serotonin, gama 
aminobutyric acid (GABA), glutamate, and endorphins are released.3  Dopamine causes 
stimulation and pleasure as well as decreases anxiety.  These psychoactive effects on the 
body lead to the addictive nature of nicotine.3  Catecholamines released are responsible 
for increasing heart rate and contractility and constricting coronary blood vessels leading 
to increased blood pressure.  These catecholamines also constrict blood vessels in the 
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skin resulting in restricted blood flow and increased vascular resistance.3   Nicotine also 
contributes to insulin insensitivity.3    
Some of the potential harmful effects of nicotine include nicotine intoxication, 
increased rates of atherosclerosis formation, hypertension, myocardial infarction, stroke, 
sudden death, peptic ulcer disease, esophageal reflux, delayed wound healing, fetal 
neurotoxicity, spontaneous abortion, premature labor, and low birth weight neonates.4  
Tobacco smoke contains many toxic and carcinogenic chemicals that contribute to the 
development of disease and ultimately death.   
Smoking cessation can reduce the risk of developing these diseases and slow their 
progression.  Smoking cessation leads to withdrawal symptoms that include irritability, 
restlessness, depressed mood, anxiety, impaired concentration, increased appetite, and 
difficulty sleeping.3  Tobacco dependence is behavioral, cognitive, and physiological.5  
Smoking cessation often requires multiple attempts before a person is successful.  
Most smokers attempt to quit on their own, which is the least successful method of 
quitting.  It has been reported that approximately 80% of smokers who try to quit on their 
own relapse within one month.  Only 3% of smokers achieve sustained abstinence.6   
Treatments exist that can improve the long-term success for those wishing to quit.  These 
treatments include counseling, nicotine replacement therapy (NRT), and non-nicotine 
medications.7  In a 2002 meta-analysis, the investigators reported a 7% long term 
successful abstinence using over-the-counter NRT.8  Their use is very low among 
smokers during attempts at quitting .  This highlights the need for unique products that 
will increase the use and success of smoking cessation treatment.   
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Electronic nicotine delivery devices (ENDD), in the form of electronic cigarettes, 
arrived on the market in 2004.  The first electronic cigarette was marketed by a Chinese 
company, Ruyan®.9  Electronic cigarettes resemble a cigarette and are powered by a 
battery.  They are activated by the act of drawing on the mouthpiece.  Each time a person 
draws on the mouthpiece, the nicotine-propylene glycol solution held in a cartridge at the 
end of the device is vaporized.  The appearance of the vapor resembles smoke.  However, 
the vapor does not contain combustion products.  The electronic cigarette is increasing in 
popularity worldwide as a cessation/reduction product.  Users report using the product to 
quit/reduce smoking and mitigate the withdrawal effects of smoking cessation while still 
continuing to have a “smoking experience.”9    
Research of the efficacy and safety of electronic cigarettes as a short or long-term 
smoking cessation tool is limited.  In December 2009, Bullen et al10 reported the Ruyan® 
16 mg electronic cigarette reduced desire to smoke with minimal adverse effects during 
participants 9-hour exposure.  Serum cotinine can be used as a way to quantify the intake 
of nicotine.4  In the 2010 study, A Clinical Laboratory Model for Evaluating the Acute 
Effects of Electronic “Cigarettes”: Nicotine Delivery Profile and Cardiovascular and 
Subjective Effects,11 the authors concluded that ten puffs using an electronic cigarette 
exposed participants to no measurable nicotine or CO and did not result in increased heart 
rate.  In contrast, Flouris et al12 reported that serum cotinine levels after electronic 
cigarette use was similar to those seen in cigarette smoking with no significant 
interference in lung function in January 2013.  Also in January 2013, Goniewics et al13 
reported the vapor produced with electronic cigarette use contained potentially toxic 
elements.  However, the levels detected were 9-450 times less than those found in usual 
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cigarettes.  The authors supported the use of electronic cigarettes as a tool to reduce 
harm.13 
The aim of this systematic literature review was to summarize what is known and 
what contribution further research can offer regarding the efficacy and safety of 
electronic cigarettes as a smoking cessation product.           
METHODS 
An exhaustive medical literature search was performed using Medline-OVID, 
CINAHL, and Health Reference Center-Academic using the keywords: electronic 
cigarette, e-cigarette, and e cigarette.  The search was refined to include only those 
articles that were English language and included human research participants.  The 
references of these articles were reviewed for relevant articles.  Articles with first-hand 
research data evaluating the efficacy and safety of electronic cigarettes were included.  
The included articles were assessed for quality utilizing the Grading of 
Recommendations, Assessment, Development, and Evaluation (GRADE).14  Lastly, a 
search of the National Institute of Health (NIH) clinical trials website revealed currently 
registered trials examining the efficacy and safety of electronic cigarettes in smoking 
cessation.  This search revealed eleven trials currently registered, eight currently 
recruiting, one not yet recruiting and two active but not recruiting. 
RESULTS 
The search of Medline-OVID, CINAHL, and Health Reference Center-Academic 
produced a total of 293 articles to be reviewed.  After reviewing these articles for 
relevance to smoking cessation and efficacy, three articles met the inclusion criteria.  
There were two randomized controlled trials and one observational study.    
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Bullen et al. 
This randomized controlled trial investigated the effect of 16 mg electronic 
cigarettes, nicotine-free electronic cigarettes, and nicotine patches on smoking cessation 
as well as adverse effects (serious and non-serious) during the 6-month study period.  
Analysis of the electronic cigarette confirmed that the vapor liquid did not contain 
diethylene glycol, which is a toxin.  Analysis also determined that the cartridges labeled 
16 mg contained anywhere from 10-16 mg/mL of nicotine and those labeled nicotine-free 
did not contain nicotine.  The primary outcome of the study was continuous smoking 
abstinence defined as ≤ 5 cigarettes during the 6 months after their quit date.  Study 
participants self-reported abstinence.  Exhaled carbon monoxide (eCO) levels were 
measured as a confirmation of non-smoking status (‹10 ppm).  The secondary outcomes 
were continuous abstinence, 7-day point prevalence abstinence, number of cigarettes/day, 
time to relapse, number of patches or cartridges used, other cessation treatments used, 
withdrawal symptoms, stage of addiction, smoking latency, and adverse events.  It was 
not reported how the data on the number of  cigarettes/day, time to relapse, number of 
patches or cartridges used, other cessation treatments used, withdrawal symptoms, stage 
of addiction, smoking latency, and adverse events were compiled.  It appears that they 
were reported by participants to Quitline, a behavioral support organization.  Secondary 
outcomes were assessed at 1, 3, and 6 months following quit dates. 15   
The study included 657 adult smokers recruited from community newspapers in 
Auckland, New Zealand.  The eligibility criteria for the study were smokers 18 years and 
older who had smoked 10 or more cigarettes/day for the past year, and interested in 
smoking cessation.  Interested parties were excluded from the study if they were pregnant 
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or breastfeeding, were using cessation drugs or in an existing cessation program, reported 
myocardial infarction, stroke, or severe angina in the past 2 weeks, and were those with 
poorly controlled medical disorders, allergies, or chemical dependence.  Those who met 
the inclusion criteria were randomized to the 16 mg nicotine electronic cigarette, 
nicotine-free nicotine electronic cigarette, or nicotine patch groups by the study 
statistician in a 4:4:1 ratio via a computerized block randomization, block size nine, 
stratified by ethnicity, sex, and level of nicotine dependence.  Withdrawal symptoms and 
stage of addiction at baseline were assessed using the Autonomy over Tobacco Scale 
(AUTOS). 15  AUTOS is a tool used to determine psychological dependence, withdrawal, 
and cue-induced urges as they relate to tobacco addiction. 16  
All participants’ were administered the Glover Nilsson Smoking Behavioral 
Questionnaire (GN-SBQ) to determine their behavioral dependence.17 
The group allocations were 289 to the 16 mg electronic cigarettes group, 73 to the 
nicotine-free nicotine electronic cigarettes group, and 295 to the nicotine patches group.  
Those allocated to the 16 mg electronic cigarettes and nicotine-free electronic cigarettes 
were provided an e-cigarette, spare battery and charger, and cartridges (with labels 
masked to nicotine content) accompanied by instructions to use them as desired for 1 
week before and up to 12 weeks after their chosen quit date.  Those allocated to the 
nicotine patch were provided exchange cards that could be taken to a community 
pharmacy and instructions to use them daily for 1 week before and up to 12 weeks after 
their chosen quit date.  Allocation blinding of the participants to the electronic cigarettes 
and patches was not possible.  Participants allocated to the electronic cigarette groups 
were blinded as far as their allocation between 16 mg electronic cigarettes and nicotine-
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free electronic cigarettes.  Participants were blinded within the electronic cigarette groups 
through masking of the nicotine content on the labels of the products.  However, the 
research assistants responsible for performing the outcome assessments were blinded to 
group allocation. 15 
All participants were referred to Quitline, who provided telephone-based 
behavioral support.  Participation in Quitline was not required by the study.  Quitline 
provided the researchers with usage reports. 15  
The study groups were similar with respect to known prognostic variables at the 
beginning of the study.  Loss to follow-up was 48/289 (22%) in the 16 mg electronic 
cigarette group, 80/295 (27%) in the nicotine patch group and 16/73 (22%) in the 
nicotine-free electronic cigarette group.  All patients were analyzed in the group to which 
they were first allocated with an intention to treat philosophy. 15  
The cessation rate 6 months after quit date was highest in the 16 mg nicotine 
electronic cigarette group at 21/289 (17%).  The cessation rate 6 months after quit date in 
the nicotine patch group was 17/295 (5.8%).  In comparing these two groups, there was a 
relative risk of 2.9 and a number needed to treat (NNT) of 9.  The cessation rate 6 months 
after quit date in the 0mg nicotine electronic cigarette groups was 3/73 (4.1%).  When 
comparing this group with the 16 mg e-cigarette group, there was a relative risk was 4.1 
and a NNT of 8 results.  The abstinence rate was much lower than anticipated and the 
authors stated that there was “insufficient statistical power to conclude superiority of the 
nicotine e-cigarettes to patches or to placebo e-cigarettes.”15  The 7-day point prevalence 
cessation rate 6 months after the quit date was highest in the nicotine-free electronic 
cigarette group at 16/73 (21.9%).  The 7-day point prevalence cessation rate 6 months 
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after quit date in the 16 mg nicotine electronic cigarette group at 61/289 (21.1%).  The 7-
day point prevalence cessation rate 6 months after quit date in the nicotine patch groups 
was 46/295 (15.6%).15   
The researchers compared the performance of 16 mg nicotine electronic cigarettes 
to nicotine patches.  The continuous abstinence 6 months after quit date for this 
comparison was: relative risk of 1.26 with a 95% CI (0.68 to 2.34) and a risk difference 
of 1.51 with a 95% CI (-2.49 to 5.51), p - 0.46.  The 7-day point prevalence abstinence 6 
months after quit date for this comparison was: relative risk 1.35 with a 95% CI (0.96 to 
1.91) and a risk difference of 5.52 with a 95% CI (-.075 to 11.79), p = 0.09.  The 
performance of 16 mg electronic cigarettes were also compared to nicotine-free 
electronic cigarettes and yielded a continuous abstinence 6 months after quit date relative 
risk of 1.77 with a 95% CI (0.54 to 5.77) and a risk difference of 3.16 with a 95% CI  
(-2.29 to 8.61), p = 0.44.  The 7-day point prevalence abstinence 6 months after quit date 
for this comparison was relative risk 0.96 with a 95% CI (0.59 to 1.57) and a risk 
difference of -0.81 with a 95% CI (-11.40 to 9.78),p = 0.88. 15 
The authors report median time to relapse in the 16 mg nicotine electronic 
cigarette group as 35 days with a 95% CI (15 to 56).  The median time to relapse in the 
nicotine patch group was reported as 14 days with a 95% CI (8 to 18), p ‹ 0.0001.  The 
median time to relapse in the nicotine-free electronic cigarette group was 12 days with a 
95% CI (5 to 34), p = 0.09. 15 
The reported difference in decrease in cigarettes/day when comparing the 16 mg 
nicotine electronic cigarette group with the nicotine patch group was 2 cigarettes/day, p = 
0.002. 15   
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The authors report that AUTO scores in the combined electronic cigarette groups 
over the 6 month follow-up period decreased 50% from baseline.  The nicotine patch 
groups’ AUTO scores decreased by 33%.  The reduction in AUTO score from baseline to 
6 months was 1.56, p = 0.02 when comparing the 16 mg nicotine electronic cigarette and 
the nicotine patch.  The reduction in AUTO score from baseline to 6 months was 1.34, p 
= 0.19 when comparing the 16 mg nicotine electronic cigarette and the nicotine-free 
electronic cigarette.15      
The GNSBQ scores of the participants scoring “strong” or “very strong” at the 
beginning of the study were balanced.  There was no evidence that there was an 
association between GNSBQ score and outcome.  The data was not shown in the article.15  
Serious side effects (death, life threatening illness, admission to hospital or 
prolongation of hospital stay, persistent or significant disability or incapacity, congenital 
abnormality, medically important) were reported as 27 in the 16 mg nicotine electronic 
cigarette group, 14 in the nicotine patch group and 5 in the nicotine-free electronic 
cigarette group.  Non-serious events were reported as 110 participants in the 16 mg 
nicotine electronic cigarette group, 105 in the nicotine patch group and 31 in the nicotine-
free electronic cigarette group.  There was a higher rate of adverse events in the 16 mg 
nicotine cigarette group overall.  When comparing adverse events in the 16 mg nicotine 
cigarette group and the nicotine patch group, the event ratio was reported to be 1.50, 95% 
CI (0.82 to 1.34), p = 0.7.  The authors believe that only one of these reported serious/non 
serious side effects in the nicotine patch group was definitely attributable to the study 
treatment and that a total of 3, (1 in each of the three study groups) was probably 
attributable to the study treatment.  A total of 10, (5 from the 16 mg nicotine electronic 
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cigarette group, 4 from the nicotine patch group and 1 from the nicotine-free electronic 
cigarette group) were possibly attributable to the study treatment. 15  
Quitline’s services were accepted by 115/289 (40%) in the 16 mg electronic 
cigarette group, 106/295 (36%) in the nicotine patch group and 26/73 (36%) in the 
nicotine-free electronic cigarette group. 15 
Participants in the 16 mg nicotine electronic cigarette group reported using 1 to 3 
cartridges/day at 1 month after quit date, 1 cartridge/day at 3 months after the quit date, 
and 0.7 cartridges/day at 6 months after the quit date.  Those in the nicotine patch group 
reported an average of 1 patch/day consistently from 1 month to 6 months after the quit 
date.  Finally, participants  in the nicotine-free electronic cigarette group reported 1.1 
cartridges/day at 1 month after the quit date, 1.2 cartridges/day at 3 months after the quit 
date and 0.7 cartridges/day at 6 months after the quit date.15   
The authors reported that in the combined 16 mg nicotine electronic cigarette 
groups, 2 used bupropion and 1 used verenicline in the 30 days prior to the 6 month 
follow-up visit.  In the nicotine-free electronic cigarette 3 used verenicline in the 30 days 
prior to 6 months from their quite dates. 15      
The first limitation of this study as identified by the authors was “the effect size 
and estimates of abstinence on which the study sample size was calculated were 
optimistic; hence, statistical power to detect differences was reduced.”  Second, the loss 
to follow-up and withdrawal rate was higher in the nicotine patch group.  The authors 
believe that participants may have been interested in the study because they were curious 
about electronic cigarettes and once randomized to the nicotine patch group, they became 
disinterested in the study.  Another possible explanation given by the authors was that 
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participants may had used nicotine patches without success in the past, and it is 
conceivable that they would have given up on the patch and withdrawn from the study.  
Third, the authors feel that the behavioral support in this study may not have been 
intensive enough and a more intensive behavioral support model may have improved 
abstinence rates. 15 
Caponnetto et al 
This double blind, randomized controlled trial18 examined the effect of 7.2 mg 
nicotine electronic cigarettes, hereafter referred to as Group A; 7.2 mg for 6 weeks, then 
transition to 5.4 mg nicotine electronic cigarettes, hereafter referred to as Group B; and 
nicotine-free electronic cigarettes, hereafter referred to as Group C; on smoking 
reduction/cessation and adverse effects (dry cough, mouth irritation, shortness of breath, 
throat irritation, and headache).  An analysis of the nicotine content of the cartridges used 
in this study was performed.  However, the report is not available in English so 
determining the actual nicotine content of the cartridges was not possible for this review.  
The primary outcome of the study was › 50% reduction in cigarettes/day at the 52-week 
study visit from baseline.  The secondary outcome was sustained smoking abstinence at 
the 52-week study visit.  Study participants self-reported the number of cigarettes/day.  
Exhaled carbon monoxide (eCO) levels were measured as a confirmation of smoking 
status and reduction from baseline.  Participants kept a diary detailing product use 
(number of cartridges used), tobacco cigarettes smoked (cigs/day), withdrawal symptoms 
and adverse events. 18 
The study included 300 participants recruited from advertisements in a local 
newspaper in Catania, Italy.  The eligibility for study inclusion was adult smokers in 
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good health, age 18-70 yrs., using ≥ 10 factory made cigarettes/day for at least the past 
five years, not attempting /wishing to quit in the next 30 days.  Exclusion criteria for the 
study were symptomatic cardiovascular disease, symptomatic respiratory disease, regular 
psychotropic medication use, current or past history of alcohol abuse, use of smokeless 
tobacco or nicotine replacement therapy, pregnancy or breastfeeding. 18   
Participants were randomized by a computer generated randomization sequence 
with a block size of 15 and an allocation ratio of 5:5:5.  Each group contained 100 
participants.  External packaging was identical for all three strengths of cartridges in 
order to blind group allocation.  The authors do not explicitly explain the blinding of the 
investigators to group allocation.  A local distributor provided the study supplies (two 
rechargeable batteries, a charger, two atomizers along with instructions on how to charge, 
activate and correctly use the electronic cigarette) free of charge to the participants.  The 
groups were provided with an electronic cigarette kit and enough cartridges to last until 
each follow-up visit.  Participants were not encouraged or given any motivation to cease 
smoking. 18   
Study participants were instructed to use the product ad libitum throughout the 
day, not to exceed a 4 cartridge/day maximum as recommended by the manufacturer of 
the product.  Participants attended follow-up visits at 2, 4, 6, 8, 10, 12, 24, and 52 weeks.  
At each of these visits, participant eCO levels were recorded, study diaries were given to 
study personnel and unused study products were turned in.  After 12 weeks, no additional 
cartridges were provided to the participants.  However, participants were told they could 
continue to use the electronic cigarettes.  Saliva cotinine levels were measured at 6 and 
12 weeks in participants who reported no smoking and had an eCO ≤ 7 ppm.  Study 
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groups were similar with respect to prognostic variables.  Loss to follow-up was 35/100 
(35%) in Group A, 37/100 (37%) in Group B, 45/100 (45%) in Group C.  All patients 
were analyzed in the group to which they were first allocated with an intention to treat 
philosophy. 18     
At week 52, 10/100 (10%) of those allocated to Group A, 9/100 (9%) of those 
allocated to Group B 12/100 (12%) of those allocated to Group C had reduced their 
cigarettes/day by ≥ 50%, p = 0.24. 18  
At week 52, 13/100 (13%) of those allocated to Group A, 9/100 (9%) of those 
allocated to Group B and 4/100 (4%) of those allocated to Group C had achieved 
smoking abstinence and had eCO concentrations of ≤ 7 ppm, p = 0.24.18 
Self-reported adverse effects by the remaining 183 participants of the study at 52-
weeks are as follows: throat irritation 37/183 (20.2%), mouth irritation 34/183 (18.6), dry 
cough 37/183 (20.2%), headache 5/183 (2.7%), shortness of breath 15/183 (8.1%).  No 
serious adverse effects were reported during the study. 19  These figures were extracted 
from graphs contained in the article.  They were not reported in written form.18   
The authors identified several limitations of this study.  First, the study design 
was such that the investigators recruited smokers not interested in smoking cessation.  As 
a result, direct comparison with other smoking cessation products is not feasible.  
Secondly, the study was designed with the concept that nicotine is the main culprit 
leading to smoking addiction.  The study did not include a “control group specifically for 
e-cigarette use.”  Third, approximately 40% of the study participants were lost to follow-
up.  Fourth, there were frequent technical difficulties with the e-cigarettes used in the 
study.  Fifth, the model of e-cigarette used in the study is no longer available.  The e-
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cigarettes currently available perform at a much high level than those used in the study.  
Sixth, the population from which the study participants were recruited adhered to a so-
called “coffee puff-break,” whereby work or leisure activities were halted and everyone 
drank coffee and smoked tobacco products.  Finally, withdrawal symptoms could have 
been subject to recall bias18  
Polosa et al 
This observational study19 examined the effect of electronic cigarettes with 7.4 mg 
nicotine liquid on reduction/cessation of smoking as well as adverse events (ie., throat 
irritation, mouth irritation, sore throat, dry cough, dry mouth, mouth ulcers, dizziness, 
headache, and nausea) over a 24-week period.  Following random analysis, it was 
confirmed that the nicotine content per cartridge used in the electronic cigarettes was 7.25 
mg  The primary outcome of the study was › 50% reduction in cigarettes/day for a 30-day 
period prior to the 24-week study visit from baseline.  The secondary outcomes were › 
80% reduction in cigarettes/day for a 30-day period prior to the 24-week study visit from 
baseline and sustained smoking abstinence for a 30-day period prior to the 24-week study 
visit.  Study participants self-reported the number of cigarettes/day.  Exhaled carbon 
monoxide (eCO) levels were measured as a confirmation of smoking status and reduction 
from baseline.  Participants kept a diary detailing product use (number of cartridges 
used), tobacco cigarettes smoked (cigs/day) and adverse events. 19 
The study included 40 adult smokers recruited by local hospital staff in Catania, 
Italy.  The eligibility criteria for the study was healthy smokers 18-60 years, smoking ≥ 
15 factory made cigarettes/day for at least ten years and not currently wanting or 
attempting to quit smoking in the following 30 days.  Interested parties were excluded 
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from the study if they reported a history of alcohol or illicit drug use, major depression or 
other psychiatric condition, recent myocardial infarction, angina pectoris, high blood 
pressure (BP ›140/90), diabetes mellitus, severe allergies, poorly controlled asthma or 
other airway diseases.  Given that this was an observational study, the participants were 
not randomized.  All participants were provided with the 7.4 mg electronic cigarettes, 
instructed on proper operation of the product and instructed to use the product ad libitum 
throughout the day, not to exceed a 4 cartridge/day maximum as recommended by the 
manufacturer of the product. 19 
Those included in the study were scheduled to return for study visits at 4, 8, 12 
and 24 weeks.  At each of these visits, participant eCO levels were recorded, study diaries 
were given to study personnel, and unused study products were turned in.  Participants 
were not encouraged or given any motivation to cease smoking.  However, smoking 
cessation assistance was provided to those who asked for assistance.  If this occurred, the 
participant was removed from the study.  The number of participants removed under 
these circumstances was not reported.19 
Twenty-seven participants attended all study visits.  Thirteen participants were 
lost to follow-up.  Those lost to follow-up were included in the 24 week analysis as part 
of the study’s intention to treat analysis.  It is of note that there were a larger number of 
males lost to follow-up than females.  The authors report an overall 80% reduction in 
median cigarette/day use (25 to 5), p ‹ 0.001.  Of the 40 participants, 13 (32.5%) 
exhibited a sustained › 50% reduction in cigarettes/day, p ‹ 0.001, 5 (12.5%) exhibited a 
sustained › 80% reduction in cigarettes/day, p= 0.043, and 9 (22.5%) exhibited sustained 
abstinence, p = 0.008.  Self-reported adverse effects by the remaining 27 participants of 
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the study at 24 weeks are as follows: throat irritation 4/27 (14.8%), mouth irritation 2/27 
(7.4%), dry cough 3/27 (11.1%), dry mouth, 1/27 (3.7%), dizziness 1/27 (3.7%), 
headache 1/27 (3.7%), nausea 1/27 (3.7%).  No serious adverse effects were reported 
during the study. 19 
There were several limitations identified by the authors.  First, there was a 
limitation due to the small size of the study as well as the result of chance and no true 
outcome due to the uncontrolled nature of the design.  Due to this, the authors believe the 
results should be viewed with caution.  Second, there was 13/27 (32.5%) loss to follow-
up.  Third, because the participants were unwilling to quit and the electronic cigarette was 
used throughout the study; a comparison with other smoking cessation products cannot be 
made.  Fourth, there were technical defects with the electronic cigarettes, which could 
have contributed to the number loss to follow-up as well as participants failure to cease 
smoking.  Lastly, typical withdrawal symptoms usually seen in smoking cessation studies 
were not reported by the participants.  This could be the result of the fact that identifying 
these symptoms was not rigorous in the study, which could have resulted in recall bias. 19 
DISCUSSION 
Electronic cigarettes represent another potential smoking cessation product that is 
not currently being offered in the healthcare setting in the United States.  Some 
consumers are already using electronic cigarettes as a smoking cessation product while 
others are using them to mitigate withdrawal symptoms due to increasing smoking 
restrictions in the United States.  Still, other consumers see them as a way to continue 
having a smoking experience without the harmful effects and smell of tobacco cigarettes.  
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In 2008, WHO agreed that the electronic cigarette might prove a useful tool in smoking 
cessation and that studies were needed to confirm their efficacy and safety.20  WHO 
confirmed that the actual content of the cartridges used in electronic cigarettes varies 
according to testing that has been done.  As a result, there is no way for the consumer to 
be sure what level of nicotine and other chemicals are in various electronic cigarette 
cartridges.  As a result, in July of 2013, consumers were advised not to use electronic 
cigarettes until specific products have been evaluated for their efficacy and safety.21  The 
US Department of Health and Human Services stated that electronic cigarettes contain 
ingredients known to cause toxicity in humans and that no studies addressing the safety 
of electronic cigarettes have been submitted to the FDA.  Due to this, consumers don’t 
know what chemicals are in the cartridges, how much nicotine is in each cartridge, or if 
they are safe for use.  The FDA has not approved any electronic cigarettes for therapeutic 
use as of January 17, 2014.  There are countless brands of electronic cigarettes available 
in the United States.  Currently there isn’t any regulatory body in the United States that is 
overseeing consistency in these products.  In Fall 2013, the FDA issued a proposed rule 
which will allow the FDA to oversee the use and safety of electronic cigarettes.22    
The studies15,18,19 all illustrated favorable smoking cessation rates with limited 
adverse effects.  However, there are several concerns that still limit their use as a routine 
smoking cessation product.  Inconsistent manufacturing practices do not guarantee the 
consumer that the package labeling accurately reflects the true nicotine content and toxins 
contained in the e-cigarette.  Also, to date, no studies have published results of studies 
lasting more than one year; therefore, the effects of long-term use are not known.   
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Bullen et al15 recognized several limitations to their study.  The first limitation of 
this study as identified by the authors was “the effect size and estimates of abstinence on 
which the study sample size was calculated were optimistic; hence, statistical power to 
detect differences was reduced.”  Second, the loss to follow-up, and withdrawal rates 
were higher in the nicotine patch group.  This may have been due to curiosity about 
electronic cigarettes and when allocated to the nicotine patch group, participants became 
disinterested.  The loss also could have been a result of past unsuccessful usage of 
nicotine patches.  Finally, the Quitline behavioral support offered in the study may not 
have been intensive enough and the researchers believe that more intensive behavioral 
support may have improved abstinence rates.  
Caponnetto et al18  reported that inclusion criteria required that respondents not be 
attempting or interested in smoking cessation.  This may have caused the findings of the 
study to be undervalued due to the participants’ lack of desire to quit smoking.  The study 
was designed with the concept that nicotine is the main culprit leading to smoking 
addiction.  The study did not include a “control group specifically for e-cigarette use.”  
There was a significant loss to follow-up, approximately 40%.  However, the analysis 
was performed with intention to treat analysis philosophy.  There were frequent technical 
difficulties with the electronic cigarettes used in this study.  As a result, the findings of 
the study could be undervalued due to participants ceasing to use the electronic cigarettes.  
Furthermore, the electronic cigarette used in the study is inferior to those being marketed 
today and as a result, may not have performed as well as todays’ electronic cigarettes.  
The study took place in Italy where it is a social norm to take a “coffee puff-break.”  
Electronic cigarettes might have performed better in locations where this was not the 
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social norm.  Finally, the withdrawals symptoms experienced by the participants may 
have been undervalued as a result of the symptoms being self-reported during follow-up 
visits and would be subject to potential recall bias.   
In Polosa et al19, the authors noted several study limitations.  The study was a 
small uncontrolled study and as a result, the findings may be due to chance rather than 
the electronic cigarette.  Also, there was a 32.5% loss to follow-up which is very 
significant given the small number of participants in the study.  However, the analysis 
was performed with intention to treat analysis.  Again, there were technical defects with 
the electronic cigarettes which could have contributed to the number loss to follow-up.  
As a result, the findings of the study could be undervalued due to participants ceasing to 
use the electronic cigarettes.  One of the inclusion requirements of the study was that the 
respondents had to not be attempting or desiring to stop smoking.  As a result, the 
readiness to quit of those included in the study was not assessed.  The findings of the 
study may be undervalued as a result of the participants’ lack of desire to quit smoking.  
Finally, the withdrawals symptoms experienced by the participants may have been 
undervalued as a result of the symptoms being self-reported during follow-up visits and 
would be subject to potential recall bias.  
CONCLUSION  
The studies reviewed demonstrate that the specific electronic cigarettes studied are 
effective and do not exhibit any significant adverse effects as a smoking cessation 
product.  However, the studies also demonstrated that the labeling found on the cartridges 
used in the studies did not correctly reflect the nicotine content.  The combined quality of 
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the three studies reviewed after assessment using GRADE criteria is moderate.  There is 
insufficient evidence to properly assess the benefits and harms of electronic cigarettes 
due to inconsistencies in the manufacturing process.  There is a lack of evidence to 
support routinely recommending the use of electronic cigarettes for smoking cessation at 
this time.  Further randomized controlled studies examining the efficacy and safety are 
currently in process.  These studies are expected to further clarify the efficacy and safety 
of electronic cigarettes as a smoking cessation product.  
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Table I. Characteristics of Reviewed Studies 
 
 
Quality Assessment 
Study Design Limitations Inconsistency Indirectness Imprecision Factors 
Increasing 
Quality 
Quality 
Bullen et al.15 Randomized 
Controlled 
Trial 
Very 
Serious a,b 
No Serious No Serious No Serious Upgrade 1 
Level c 
Moderate 
Caponnetto et al.18 Randomized 
Controlled 
Trial 
Serious a No Serious No Serious No Serious Upgrade 1 
Level c 
High 
Polosa et al.19 Observational Serious a No Serious Serious d Serious e None Very Low 
 
a
 High attrition rate. 
b Group allocation of patients to the e-cigarette and nicotine patches could not be concealed from the participants.  However, they were 
concealed from the research assistants performing the outcome assessments. 
c All plausible confounders would underestimate the treatment effect. 
d Smoking cessation is not the primary outcome of the study.  
e Small sample size 
 
